A detailed history of China Universal Asset Management Co., Ltd. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 11,329 shares of PTGX stock, worth $539,486. This represents 0.06% of its overall portfolio holdings.

Number of Shares
11,329
Previous 6,891 64.4%
Holding current value
$539,486
Previous $238,000 113.87%
% of portfolio
0.06%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$33.72 - $47.33 $149,649 - $210,050
4,438 Added 64.4%
11,329 $509,000
Q2 2024

Jul 19, 2024

SELL
$24.66 - $34.8 $106,062 - $149,674
-4,301 Reduced 38.43%
6,891 $238,000
Q1 2024

Apr 29, 2024

BUY
$21.79 - $32.15 $98,425 - $145,221
4,517 Added 67.67%
11,192 $324,000
Q4 2023

May 21, 2024

SELL
$14.05 - $23.44 $63,463 - $105,878
-4,517 Reduced 40.36%
6,675 $153,000
Q4 2023

Jan 23, 2024

BUY
$14.05 - $23.44 $73,088 - $121,934
5,202 Added 353.16%
6,675 $153,000
Q3 2023

May 21, 2024

BUY
$16.68 - $23.66 $12,059 - $17,106
723 Added 96.4%
1,473 $24,000
Q3 2023

Oct 30, 2023

BUY
$16.68 - $23.66 $12,059 - $17,106
723 Added 96.4%
1,473 $25,000
Q2 2023

May 21, 2024

BUY
$18.02 - $29.36 $1,495 - $2,436
83 Added 12.44%
750 $20,000
Q2 2023

Jul 27, 2023

BUY
$18.02 - $29.36 $1,495 - $2,436
83 Added 12.44%
750 $21,000
Q1 2023

May 21, 2024

BUY
$10.78 - $25.38 $1,800 - $4,238
167 Added 33.4%
667 $15,000
Q1 2023

Apr 27, 2023

BUY
$10.78 - $25.38 $1,800 - $4,238
167 Added 33.4%
667 $15,000
Q4 2022

May 21, 2024

SELL
$7.36 - $11.17 $78,693 - $119,429
-10,692 Reduced 95.53%
500 $5,000
Q4 2022

Jan 31, 2023

BUY
$7.36 - $11.17 $294 - $446
40 Added 8.7%
500 $5,000
Q3 2022

Oct 21, 2022

BUY
$7.86 - $11.71 $3,615 - $5,386
460 New
460 $4,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.34B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.